Faculty
Renato G. Martins, MD, MPH
Medical Director of Outpatient Services
Seattle Cancer Care Alliance
Thoracic/Head and Neck
Division of
Medical Oncology
Associate Professor
Department of Medicine
Mailing Address
Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-940
Seattle, WA 98109-1023
Admin Contact
Jeremy Puma
206.288.2048
hnlprogram@seattlecca.org
Fax: 206.288.2226
Specialty / Expertise
Head, Neck, Lung, and Thyroid Cancer
Research Interests
Cancer of:
- Head
- Neck
- Lung
- Thyroid
Current Research Projects
Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Vs. Cisplatin & Radiotherapy in Pts. w/ Stg III or IV Squamous Cell Carcinoma of the Head & Neck.
Role: Principal Investigator.
A Phase II Study of Intermittent Gleevec (imatinib mesylate) & Weekly Paclitaxel in Patients Aged 70 or Older with Advanced non-Small Cell Lung Cancer.
Role: Principal Investigator.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non‑small Cell Lung Carcinoma who have EGFR-positive Tumors.
Role: Co-Investigator.
Registration Phase III Study of Lucanix (belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blind, Placebo-controlled Study of Lucanix Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy.
Role: Co-Investigator.
Phase II, Multicenter, Open-Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology.
Role: Principal Investigator.
A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer.
Role: Principal Investigator.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Of ASA404 In Combination With Docetaxel As Second-Line Treatment For Locally Advanced Or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC).
Role: Co-Investigator.
An Open-Label Phase II Multicenter Study Of The Safety And Activity (As Measured By FDG PET Imaging Changes) Of The Combination Of Erlotinib And Pertuzumab In Patients With Relapsed Non-Small Cell Lung Cancer.
Role: Co-Investigator.
Phase I/II, Open-Label, Randomized Study Of The Safety, Efficacy, and Pharmacokinetics of Erlotinib With or Without PF-02341066 in Patients With Advanced Non-Small Cell Adenocarcinoma of the Lung.
Role: Co-Investigator.
A Phase 2, Open-label Trial of PF-00299804 in Untreated Advanced Adenocarcinoma of the Lung in Never or Former Light Smokers.
Role: Principal Investigator.
Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Role: Co-Investigator.
A Phase 3, randomized, open label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event.
Role: Co-Investigator.
A Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck.
Role: Co-Investigator.
A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer.
Role: Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer.
Role: Principal Investigator.
Training
Dr. Martins received his MD from Federal University of Rio de Janeiro, Brazil. He completed his Internal Medicine Residency at Gundersen Clinic, La Crosse, WI . He was a Post-Doctoral Fellow in Hematology/Oncology at Massachusetts General/Harvard Medical School, Boston, MA.
Selected Publications
Fidias P, Supko JG, Martins R, et al. A phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced non-small Cell Lung Cancer. Clin Cancer Res 7: 3942-9, 2001.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.
Martins RG. Treatment of Locally-Advanced Non Small Cell Lung Cancer with Combination of Chemotherapy and Radiation. Seminars in Respiratory & Critical Care Medicine 26(3): 273-77, 2005.
Martins RG, Dienstmann R, de Biasi P, Dantas K, Santos V, Toscano E, Roriz W. Zamboni M, Sousa A, Smaill IA, Moreira D, Ferreira CG, Zukin M. Phase II trial of neoadjuvant chemotherapy using alternating doublet in non-small-cell lung cancer. Clinical Lung Cancer 2007 Jan;8(4):257-63.
Bauman JE, Eaton KD, and Martins RG. Antagonism of Platelet-Derived Growth Factor Receptor in Non-Small Cell Lung Cancer: Rationale and Investigations. Clin Cancer Res. 2007 Aug 1;13(15):4632s-6s.
Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.
Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr. Small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):294-314.
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20;26(15):2442-9.
Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care May;14(5):297-306, 2008.
Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. Ann Thorac Surg. 2008;86:1632-9.
Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol. 2010 Mar;21(3):556-61.
Eaton KD, Martins RG. Maintenance chemotherapy in non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul;8(7):815-21. Review.
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer. J Clin Oncol. 2010 Nov 20;28(33):4953-60.
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell F, Dziadziuszko R, Richardson K, Richardson F, Wolf JL, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn Jr PA, Camidge DR. Erlotinib Alone Superior in Patients with Activating EGFR Mutations: A Randomized Phase II Biomarker Selected Study Comparing Erlotinib to Erlotinib Intercalated with Chemotherapy in 1st Line Therapy for Advanced Non-Small Cell Lung Cancer. J Clin Oncol. 2011 Sep 10;29(26):3567-3573.
A Shaw, DN Hayes, R Martins. The Importance of Histology and Molecular Testing (EGFR and EML4-ALK) in the Initial Evaluation of Advanced Non-small Cell Lung Cancer. 2011 ASCO Educational Book 292-298.
Martins RG, D’Amico TA, Loo BW, Pinder-Schenck M, Borgaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. Accepted for publication in JNCCN, May 2012.
Last updated: March 2012